Nexalin's DIFS™ Technology Shows Efficacy in Reducing Self-Injury and Depression in Adolescent Females

Nexalin Technology, Inc. announced the publication of a peer-reviewed study in BMC Psychiatry, highlighting the effectiveness of its Differentiated Integrative Frequency Stimulation (DIFS™) technology. The study, conducted by researchers at the University of California, San Diego (UCSD), investigated the impact of Nexalin's non-invasive neurostimulation device on female adolescents experiencing self-injury and depression symptoms. The findings indicate statistically significant reductions in both self-injury behaviors and depressive symptoms among the participants.

The research further provided insights into the neurological mechanisms underlying these improvements. Brain-network findings from the study reportedly offer additional support for the differentiated nature and efficacy of Nexalin's non-invasive approach. This publication marks a significant step for Nexalin Technology, as it provides scientific validation for their therapeutic device in a vulnerable patient population.

The study focused specifically on female adolescents, a demographic often grappling with mental health challenges such as depression and self-injury. The positive outcomes reported suggest a potential new avenue for treatment in this group. Nexalin's DIFS™ technology is described as a non-invasive neurostimulation method, distinguishing it from more traditional or invasive therapeutic interventions for mental health conditions.